AB023 reduces dialyzer clotting compared to placebo during heparin-free dialysis, and continues to be safe and well tolerated

Services segment in the dialysis market is predicted to expand at a CAGR of more than 4.5% by 2027 due to increased adoption of dialysis services for the treatment of several chronic kidney disorders.

Presentation to include clinical data from Aronora's phase 2 study of AB023, a factor XI-targeted antibody that is being developed for the treatment and prevention of thrombosis and inflammation.

UVMC's Dialysis Center staff does everything it can to make those receiving dialysis feel at home.